TSEAC to discuss BSE
This article was originally published in The Tan Sheet
Executive Summary
FDA Transmissible Spongiform Encephalopathies Advisory Committee will meet July 17-18 to consider whether results of five gelatin studies conducted with European Commission funding demonstrate a reduction in infectivity from BSE sufficient to protect human health. Committee will discuss safety of bovine bone gelatin in oral and topical drugs, cosmetics and recommend changes to FDA position if necessary. All five studies, released July 11 on 1FDA's Web site, tested "gelatin manufacturing processes...using artificially high infective raw material [and] resulted in a final gelatin which, after purification, has not induced TBSE disease after intracerebral injection in animals of the same species." TSEAC meeting will take place at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...
You may also be interested in...
FDA TSE Bovine Gelatin Guidance Revisions Recommended By Panel
FDA should clarify its recommendations to industry about safe sources of bovine bone gelatin for use in dietary supplements, drugs and cosmetics, a majority of the agency's Transmissible Spongiform Encephalopathies Advisory Committee agreed at a July 17 meeting in Bethesda, Md
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.